# A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Source: https://onco.cc/trials/nct04752813/  
OnCo record `nct04752813` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Temozolomide in glioma & glioblastoma, run by BPGbio, active and no longer recruiting.

## Summary

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) is a phase 2 interventional study registered as NCT04752813 by BPGbio, with 50 participants enrolled, started 2022-08-22 and due to reach its primary completion in 2026-08-25. Interventions recorded: BPM31510, Temozolomide (TMZ) and Radiation.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04752813
- Phase: 2
- Setting: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
- Sponsor: BPGbio
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT04752813: https://clinicaltrials.gov/study/NCT04752813

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct04752813.json